Mirum Pharmaceuticals $200 million private placement
We advised the placement agents on the transaction
Davis Polk advised the placement agents in connection with Mirum Pharmaceuticals, Inc.’s $200 million private placement of common stock and pre-funded warrants.
Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. The proceeds from the private placement are intended to fund clinical development and commercial activities following the proposed acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The closing of the private placement is contingent upon the closing of the proposed acquisition.
The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Savannah J. Dowling and Alexis Aguila Johnson. All members of the Davis Polk team are based in the Northern California office.